Home›Trial›NCT04499248
🔬NCT04499248Phase 1Phase 2RECRUITING

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Study Summary

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

Conditions
Open-angle GlaucomaOcular Hypertension
Interventions / Drugs
AGN-193408 SRLumiganSham AdministrationLumigan VehicleAGN-193408 SRSham AdministrationLumigan Vehicle
View on ClinicalTrials.gov ↗
Sponsor
ABBV
AbbVie Inc
Immunology
C64/100
Study Details
Enrollment96 participants
Primary Completion—
Lead SponsorAbbVie
Data Retrieved2026-04-11 02:51:51.325140+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.